Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

The Caribbean's IC24 fleet was the marquee one-design action at the breezy St. Thomas International Regatta. Calm, cool, and ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...

"It's going to be really hard for the world to catch up." Automaker unveils jet-inspired SUV with 'super impressive' features ...

The product enables broadcasters to optimize their media workflows "by leveraging the power of hardware and the flexibility ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

VX is a “living platform” that has been engineered to evolve with the industry’s needs, delivering resilient and adaptable software-defined media processing capabilities. With a deep understanding of ...

Wind was the word that started nearly every conversation as sailors talked shoreside after the second day of racing in the 51st St. Thomas International Regatta.

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...